Hypersensitivity clinical trials

Explore recruiting hypersensitivity clinical trials.

Recruiting hypersensitivity studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypersensitivity trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response.

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

(21824) A phase 3, single group treatment, open-label study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe hemophilia A

Norway, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

CA209-8KX Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy

Spain, Netherlands, Italy, Poland, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)

France, Italy, Germany, Spain, Poland, Ireland +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Preoperative Antibiotics for Mild or Moderate Acute Cholecystitis (POMMAC): A Non-inferiority, Open-label, Randomized Controlled Trial – Study Protocol

Finland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hypersensitivity trials by city

Hypersensitivity in Toronto Hypersensitivity in Vancouver Hypersensitivity in Montreal Hypersensitivity in Calgary Hypersensitivity in Edmonton Hypersensitivity in Ottawa Hypersensitivity in Winnipeg Hypersensitivity in Quebec City Hypersensitivity in Hamilton Hypersensitivity in Kitchener Hypersensitivity in London Hypersensitivity in Halifax Hypersensitivity in New York Hypersensitivity in Los Angeles Hypersensitivity in Chicago Hypersensitivity in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease